BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16926600)

  • 1. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS; Ruiz JC; Izquierdo M; Fernández-Fresnedo G; Gómez-Alamillo C; Merino R; Benito MJ; Cacho E; Rodrigo E; Palomar R; López-Hoyos M; Arias M
    Transplantation; 2006 Aug; 82(4):550-7. PubMed ID: 16926600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitors affect circulating regulatory T cells in stable renal transplant recipients.
    San Segundo D; Ruiz JC; Fernández-Fresnedo G; Izquierdo M; Gómez-Alamillo C; Cacho E; Benito MJ; Rodrigo E; Palomar R; López-Hoyos M; Arias M
    Transplant Proc; 2006 Oct; 38(8):2391-3. PubMed ID: 17097943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors.
    San Segundo D; Fábrega E; López-Hoyos M; Pons F
    Transplant Proc; 2007 Sep; 39(7):2290-2. PubMed ID: 17889166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.
    Qu Y; Zhang B; Zhao L; Liu G; Ma H; Rao E; Zeng C; Zhao Y
    Transpl Immunol; 2007 Apr; 17(3):153-61. PubMed ID: 17331841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M; Romano-Moreno S; García-Hernández M; Chevaile-Ramos JA; Layseca-Espinosa E; González-Amaro R; Portales-Pérez D
    Transpl Immunol; 2009 May; 21(1):43-9. PubMed ID: 19233271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
    Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation.
    Korczak-Kowalska G; Wierzbicki P; Bocian K; Klosowska D; Niemczyk M; Wyzgal J; Korecka A; Durlik M; Chmura A; Paczek L; Górski A
    Transplant Proc; 2007 Nov; 39(9):2721-3. PubMed ID: 18021968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low circulating regulatory T-cell levels after acute rejection in liver transplantation.
    Demirkiran A; Kok A; Kwekkeboom J; Kusters JG; Metselaar HJ; Tilanus HW; van der Laan LJ
    Liver Transpl; 2006 Feb; 12(2):277-84. PubMed ID: 16447185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
    Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M
    Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ; Garbade J; Bittner HB; Fiedler M; Dhein S; Thiery J; Mohr FW; Gummert JF
    Int Immunopharmacol; 2006 Dec; 6(13-14):2011-7. PubMed ID: 17161355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience.
    Weber T; Abendroth D; Schelzig H
    Transpl Int; 2005 Feb; 18(2):151-6. PubMed ID: 15691266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T cells in renal transplantation and modulation by immunosuppression.
    López-Hoyos M; Segundo DS; Fernández-Fresnedo G; Marín MJ; González-Martín V; Arias M
    Transplantation; 2009 Aug; 88(3 Suppl):S31-9. PubMed ID: 19667959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of donor-specific regulatory T-cell function in kidney transplant patients.
    Hendrikx TK; van Gurp EA; Sewgobind VD; Mol WM; Schoordijk W; Klepper M; Velthuis JH; Geel A; Ijzermans JN; Weimar W; Baan CC
    Transplantation; 2009 Feb; 87(3):376-83. PubMed ID: 19202442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.